Selected article for: "long term and second line"

Author: Weinhard, Jules; Noble, Johan; Jouve, Thomas; Malvezzi, Paolo; Rostaing, Lionel
Title: Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review
  • Cord-id: aykhzo8g
  • Document date: 2021_9_24
  • ID: aykhzo8g
    Snippet: Desensitization (DES) allows kidney transplantation for highly HLA-sensitized subjects. Due to the central role of IL-6 in the immunological response, tocilizumab may improve DES efficacy. Thus, we conducted a PubMed systematic review using the MeSH terms tocilizumab, interleukin-6, kidney transplantation, and desensitization. Tocilizumab (TCZ) was first studied for DES as the second-line treatment after failure of a standard DES protocol (SP) (apheresis, rituximab +/− IVIg). Although TCZ (as
    Document: Desensitization (DES) allows kidney transplantation for highly HLA-sensitized subjects. Due to the central role of IL-6 in the immunological response, tocilizumab may improve DES efficacy. Thus, we conducted a PubMed systematic review using the MeSH terms tocilizumab, interleukin-6, kidney transplantation, and desensitization. Tocilizumab (TCZ) was first studied for DES as the second-line treatment after failure of a standard DES protocol (SP) (apheresis, rituximab +/− IVIg). Although TCZ (as a monotherapy) attenuated anti-HLA antibody rates, it did not permit transplantation. However, lymphocyte immuno-phenotyping has shown that TCZ hinders B-cell maturation and thus could improve the long-term efficacy of DES by limiting anti-HLA rebound and so avoid antibody-mediated rejection. This hypothesis is supported by a recent study where clazakizumab, a monoclonal antibody directed against IL-6, was continued after kidney transplantation in association with an SP. Nine out of ten patients were then eligible for transplantation, and there were no donor-specific antibodies at 6 months post-transplantation. In association with an SP, tocilizumab does not seem to significantly improve kidney-allograft access (short-term efficacy) vs. a SP only. However, it could improve the long-term prognosis of HLA-incompatible transplantation by hindering B-cell maturation and, thereby, avoiding donor-specific antibody rebounds post-transplantation.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and lymphocyte population: 1, 2, 3
    • acute respiratory syndrome and lymphocyte profile: 1
    • acute respiratory syndrome coronavirus and long term memory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory syndrome coronavirus and lymphocyte population: 1, 2, 3
    • adaptive immune response and long term memory: 1, 2, 3
    • adaptive immune response and lymphocyte population: 1
    • adaptive immune response and lymphocyte profile: 1, 2
    • adaptive innate and long term memory: 1, 2
    • live donor and long term graft survival: 1